Axcan Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Birmingham AL United States (1991)
Status: Acquired by Aptalis (2011) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2004
NCT00490620
First Marketed Drug
2003
porfimer (photofrin)
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Axcan Pharma | Axcan Pharma inc | Axcan Pharma Inc. | AXCAN SCANDIPHARM

Indications

Approved Indications


 

Duodenal Ulcer

Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoma (Phase 3)

Adenomatous Polyposis Coli (Phase 3)

Colorectal Neoplasms (Phase 3)

Diarrhea (Phase 3)

Exocrine Pancreatic Insufficiency (Phase 4)

Fatty Liver (Phase 2)

Fibrosis (Phase 3)

Helicobacter Infections (Phase 3)

Infections (Phase 3)

Inflammation (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Liver Cirrhosis (Phase 3)

Liver Cirrhosis, Biliary (Phase 3)

Nasopharyngeal Neoplasms (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pancreatitis (Phase 4)

Pancreatitis, Chronic (Phase 4)

Proctitis (Phase 3)

Syndrome (Phase 3)

Ulcer (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 14